Another work week is coming to a close, and it’s time to look back at the top FMCG news headlines. Here’s some of the big stories on Inside FMCG this week.
Supermarket giant Coles launched a new meal plan campaign ‘What’s for Dinner’, which includes 48 recipes from ‘Mince it Monday’ to ‘Weekend Beef & Thyme Burgers’. It will be available in stores via recipe cards or by scanning QR codes on product displays. The recipes will also appear in Coles magazine and catalogue. Coles said the meals can be cooked in 30 minutes using no more than five ingredients.
Australian pharmacy Chemist Warehouse is opening its first bricks-and-mortar store in China, which will be located in Zhengzhou City, Henan Province. The discount chemist also renewed its partnership with Tmall Global for another two years to allow the retailer to expand in China and Southeast Asia It will add more stores across Alibaba’s e-commerce marketplace, Kaola and three multi-brand stores on Tmall Global under My Chemist, My Beauty Spot and Discount Vitamin Warehouse.
PepsiCo announced its first ever Green Bond priced at US$1 billion to fund its key sustainability initiatives. Simon Lowden is the new first chief sustainability officer of the soft drinks giant. Apart from leading the Sustainability Office, he will also oversee the Global Sustainable Plastics team and Global Sustainable Operations team. Ramon Laguarta, PepsiCo chairman and CEO said that issuing a bond focused on environmental sustainability reflects the company’s plan to become “faster, stronger, better”.
Consumer advocate Choice singled out “shonky” foods, fridges and finance products at the 14th Annual Shonkys awards. This year Choice called out food company Freedom Foods over its XO Crunch cereal, which it branded a “bag of sugar”. The consumer group criticised the marketing of the cereal as “a fun and nutritious way to start your kids’ day”, as the cereal contains 22.2 per cent sugar. The company said Freedom Foods XO Crunch cereal is “health washing and marketing a big bag of sugar towards our kids”.
A Philadelphia jury ordered Johnson & Johnson (J&J) to pay $US8 billion ($A11.8 billion) in punitive damages to a man who claims its antipsychotic drug, Risperdal causes abnormal growth of female breast tissue in boys. The plaintiff, Nicholas Murray, filed a lawsuit against the multinational company based on side effects of the drug; an incurable condition known as gynecomastia. US attorneys Tom Kline and Jason Itkin said in a statement that J&J is “a corporation that valued profits over safety and profits over patients”.
That’s it for this week. We’ll be back on Monday morning!